BeyondSpring Inc. (BYSI)

NASDAQ: BYSI · Real-Time Price · USD

1.700

-0.010 (-0.58%)

Jun 8, 2026, 4:00 PM EDT - Market closed

-0.58% (1D)

Market Cap	69.90M +3.3%
Revenue (ttm)	n/a
Net Income	-7.64M
EPS	-0.19
Shares Out	41.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,433
Open	1.588
Previous Close	1.710
Day's Range	1.573 - 1.710
52-Week Range	1.175 - 3.440
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropen... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 9, 2017

Employees 44

Stock Exchange NASDAQ

Ticker Symbol BYSI

Website https://beyondspringpharma.com

Full Company Profile

Financial Performance

Financial Statements

News

BeyondSpring appoints Min Qiu as CEO, Na Li as CFO

BeyondSpring (BYSI) announced a leadership transition. The leadership changes become effective July 1. The board has appointed Min Qiu as CEO of BeyondSpring, effective July 1. Qiu has been actively…

4 days ago - TheFly

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class therapies...

4 days ago - GlobeNewsWire

BeyondSpring announces updated data from 303 Study

BeyondSpring (BYSI) announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients with metastatic non-...

6 days ago - TheFly

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment...

6 days ago - GlobeNewsWire

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment ...

21 days ago - GlobeNewsWire

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Mol...

26 days ago - GlobeNewsWire

BeyondSpring Earnings release: Q1 2026

BeyondSpring released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.

26 days ago - Filings

BeyondSpring Quarterly report: Q1 2026

BeyondSpring has published its Q1 2026 quarterly earnings report on May 13, 2026.

26 days ago - Filings

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy

6 weeks ago - GlobeNewsWire

BeyondSpring Slides: Corporate presentation

BeyondSpring has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.

6 weeks ago - Filings

BeyondSpring Files 2025 Annual Report on Form 10-K

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatmen...

2 months ago - GlobeNewsWire

BeyondSpring Annual report: Q4 2025

BeyondSpring has published its Q4 2025 annual report on March 25, 2026.

2 months ago - Filings

BeyondSpring Earnings release: Q4 2025

BeyondSpring released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.

2 months ago - Filings

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...

4 months ago - GlobeNewsWire

BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress

BeyondSpring (BYSI) announced results from the Asian subset of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-typ...

6 months ago - TheFly

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...

6 months ago - GlobeNewsWire